Table 1.

Patient demographics, clinical features, preceding events, and electrophysiological features in anti-GM2 antibody reactive and non-reactive dogs.

		Abs present n = 15	Abs absent n = 10	p
Patient demographics	Age (median)	7.5 years	9 years	0.200*
	Sex	9m 6f	7m 3f	0.691†
Sampling	Onset to serum acquisition	10 days	9.5 days	0.504*
Clinical features	Ambulatory tetraparesis	26.7% (n = 4)	60.0% (n = 6)	0.122†
	Non-ambulatory paraparesis	6.7% (n = 1)	10.0% (n = 1)	1.000†
	Non-ambulatory tetraparesis	60.0% (n = 9)	20.0% (n = 2)	0.099†
	Tetraplegia	6.7% (n = 1)	10.0% (n = 1)	1.000†
	Areflexia	60.0% (n = 9)	20.0% (n = 2)	0.099†
	Hyperesthesia	33.3% (n = 5)	10.0% (n = 1)	0.341†
	Involvement of CNs	86.7% (n = 13)	70.0% (n = 7)	0.358†
	Respiratory compromise	13.3% (n = 2)	0.0% (n = 0)	0.500†
	Pneumonia	6.7% (n = 1)	10.0% (n = 1)	1.000†
	Death	13.3% (n = 2)	0.0% (n = 0)	0.500†
Preceding events	GIT infection	13.3% (n = 2)	20.0% (n = 2)	1.000†
	Respiratory infection	6.7% (n = 1)	0.0% (n = 0)	1.000†
	Vaccination	0.0% (n = 0)	0.0% (n = 0)	−
Electrophysiological features	Spontaneous activity in EMG	100% (n = 15)	90% (n = 9)	0.400†
	CMAP dispersion	53.3% (n = 8)	50.0% (n = 5)	1.000†
	CMAP amplitude decreased	93.3% (n = 14)	70.0% (n = 7)	0.267†
	F-waves normal	0.0% (n = 0)	20.0% (n = 2)	0.150†
	F-waves prolonged latency	80.0% (n = 12)	80.0% (n = 8)	1.000†
	F-waves not recordable	20.0% (n = 3)	0.0% (n = 0)	0.250†

Abs, antibodies; CMAP, compound muscle action potential; CNs, cranial nerves; EMG, electromyography; GIT, gastrointestinal.

^*Mann-Whitney U-test.

^†Fisherˊs exact test.